Oncotarget

Research Papers:

QKI5-mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis

Feng Li, Ping Yi, Jingnan Pi, Lanfang Li, Jingyi Hui, Fang Wang, Aihua Liang and Jia Yu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:32821-32834. https://doi.org/10.18632/oncotarget.8739

Metrics: PDF 2089 views  |   HTML 2765 views  |   ?  


Abstract

Feng Li1,2, Ping Yi2,3, Jingnan Pi2, Lanfang Li2,3, Jingyi Hui4, Fang Wang2, Aihua Liang1, Jia Yu2

1Institute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan, PR China

2Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, PR China

3Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, PR China

4State Key Laboratory of Molecular Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China

Correspondence to:

Jia Yu, email: [email protected]

Aihua Liang, email: [email protected]

Fang Wang, email: [email protected]

Keywords: QKI5, macroH2A1, alternative splicing, CCNL1, gastric cancer

Received: December 16, 2015     Accepted: March 28, 2016     Published: April 15, 2016

ABSTRACT

Alternative pre-mRNA splicing is a key mechanism for increasing proteomic diversity and modulating gene expression. Emerging evidence indicated that the splicing program is frequently dysregulated during tumorigenesis. Cancer cells produce protein isoforms that can promote growth and survival. The RNA-binding protein QKI5 is a critical regulator of alternative splicing in expanding lists of primary human tumors and tumor cell lines. However, its biological role and regulatory mechanism are poorly defined in gastric cancer (GC) development and progression. In this study, we demonstrated that the downregulation of QKI5 was associated with pTNM stage and pM state of GC patients. Re-introduction of QKI5 could inhibit GC cell proliferation, migration, and invasion in vitro and in vivo, which might be due to the altered splicing pattern of macroH2A1 pre-mRNA, leading to the accumulation of macroH2A1.1 isoform. Furthermore, QKI5 could inhibit cyclin L1 expression via promoting macroH2A1.1 production. Thus, this study identified a novel regulatory axis involved in gastric tumorigenesis and provided a new strategy for GC therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8739